Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
about
A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalizationMetabolic effects of indinavir in healthy HIV-seronegative menBody composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.HIV-associated lipodystrophy syndrome.Associations between breast adipose tissue, body fat distribution and cardiometabolic risk in women: cross-sectional data and weight-loss intervention.Women and HIV--revisited ten years on.Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.Nutrition in the era of highly active antiretroviral therapy.Mitochondrial toxicity and HIV therapy.NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.Strategies for treating HIV-related lipodystrophy.HIV-associated lipodystrophy: impact of antiretroviral therapy.Evaluation and management of dyslipidemia in patients with HIV infection.Antiretroviral therapies associated with lipoatrophy in HIV-infected womenFat distribution in women with HIV infection.Fat distribution in men with HIV infection.The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsRelation of body composition to body mass index in HIV-infected patients with metabolic abnormalitiesNew and emerging agents in the management of lipodystrophy in HIV-infected patients.Initial antiretroviral therapy in chronically-infected HIV-positive adults.Serum protein electrophoresis under effective control of HIV-1 disease progression.Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapyRole of microRNA biogenesis in adipocyte and lipodystrophy.Gender-specific considerations in the antiretroviral management of HIV-infected women.HIV-associated lipodystrophy syndrome: A review of clinical aspects.Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy.Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women.The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women.Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Nutrition and the HIV-associated lipodystrophy syndrome.Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy.Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia.Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors.HIV-associated metabolic and morphologic abnormality syndrome. Welcome therapy may have unwelcome effects.Breast volume is an independent predictor of visceral and ectopic fat in premenopausal women.
P2860
Q27498795-53B6281F-4CBC-4B1F-84CA-679C4494F231Q28366603-A70A264A-E384-4798-9908-1B6916735EF8Q31055878-892845AB-E6DC-4026-9194-37362B503D2BQ33821297-4E59078B-DA12-4FB0-94C0-3AA770642B6BQ33852911-B33353BB-AC84-4CF9-BA58-1150748ED252Q33926171-73BC7BE6-4FD3-43D1-89C8-341396BDCA0EQ33989249-B651C18E-A7DB-4FD3-8730-5A2B21766969Q34092346-5C57AE2E-944C-4DBA-B2D8-397406B35633Q34196934-622E3294-1198-41B8-858A-87C82E859D6DQ34255660-A140A36A-544D-4E05-81D4-93D6FEC9A80DQ34279271-76C52905-4D68-40D5-B5BD-CD546A06559CQ34459416-7C5AC7BA-960C-4B1F-AB93-1ACD8A0BA2C6Q34461377-88E67A9B-97B9-4574-BB15-0633368A5B5CQ34481623-FCF2DD09-700A-44A1-9605-7F0964456705Q34655845-56001A92-6B94-40F8-86F3-90FD2D7A8929Q34743413-6511BA71-C095-4C14-95B2-3F1471D63D2AQ35097650-9BA385E5-004A-43FF-8AE0-DD490DCF25A3Q35194384-AB145FF6-8D65-4AC7-A92A-D12A21683DC3Q35194387-477A18C5-24E0-4B7F-99A9-AAB3B38074BCQ35206623-2B708CDA-FBAF-4E88-9067-56344872C5FBQ35369261-BF501A9E-C015-4B35-860F-80A2D2F4D8E0Q35557229-481D9C55-ABF8-47CA-8617-F73AF4706A25Q35688173-34664D82-F1E1-4603-B58F-71F8531D2F07Q35728932-2F31F16D-4DC0-49FA-BA9B-9FAA4B7DE019Q35823452-4AB663FD-D607-4221-9F87-E5DFCFB424CFQ35834842-A9A414C3-294F-4F86-8607-A67CE6E5E328Q36140662-C2BA595A-A1BE-42F7-A3B9-25BD51D42472Q36171069-AA1A4BED-0A34-4C65-A593-680C9D82793BQ36447407-6193ACB7-1B11-4F49-B4FB-F154EEEE3089Q37161855-4780DD76-9A7A-4431-BBD4-2F5B94C81694Q37349834-C2243F98-B2F1-4E7C-B3B1-7278E9BE4C73Q37418489-1CB09F6B-64DE-432F-B8E4-B60F9536BBADQ37888672-B536693A-D955-4D9A-B321-65911B1BED96Q38061798-CC210C66-FC17-49AD-87E5-0DD704666E66Q38521176-734BC11B-137E-4285-BE2C-F87EE566A50CQ38964625-8290BEE3-F7B5-4F99-898E-76E0B881EAE5Q39342992-73435B7C-13E9-486F-970B-3FB16D47DB67Q40851323-69C4C901-5FC7-4A58-8FD7-C666F90B2F51Q41731830-8DE1A655-B0B1-4698-9838-513EC9D23A6CQ43256263-A81BA7DA-9C91-43A3-BF64-A569EC52ABC2
P2860
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Redistribution of body fat in ...... mbined antiretroviral therapy.
@en
Redistribution of body fat in ...... mbined antiretroviral therapy.
@nl
type
label
Redistribution of body fat in ...... mbined antiretroviral therapy.
@en
Redistribution of body fat in ...... mbined antiretroviral therapy.
@nl
prefLabel
Redistribution of body fat in ...... mbined antiretroviral therapy.
@en
Redistribution of body fat in ...... mbined antiretroviral therapy.
@nl
P2093
P1433
P1476
Redistribution of body fat in ...... mbined antiretroviral therapy.
@en
P2093
Gervasoni C
Norbiato G
Ridolfo AL
Santambrogio S
P304
P356
10.1097/00002030-199903110-00004
P407
P577
1999-03-01T00:00:00Z